Replimune Group (NASDAQ:REPL) Trading 5.5% Higher – Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL)’s stock price rose 5.5% on Wednesday . The company traded as high as $9.70 and last traded at $9.36. Approximately 958,289 shares changed hands during trading, a decline of 80% from the average daily volume of 4,806,471 shares. The stock had previously closed at $8.87.

Analyst Ratings Changes

Several research firms have recently commented on REPL. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. BMO Capital Markets cut shares of Replimune Group from a “market perform” rating to an “underperform” rating in a report on Monday, April 13th. Jefferies Financial Group reissued a “hold” rating and issued a $2.00 target price (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th. Finally, Cantor Fitzgerald cut shares of Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Seven analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $4.88.

Replimune Group Stock Performance

The stock has a fifty day moving average price of $4.92 and a two-hundred day moving average price of $7.25. The company has a market cap of $834.78 million, a P/E ratio of -2.94 and a beta of 0.91. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60.

Insider Buying and Selling at Replimune Group

In other news, insider Christopher Sarchi sold 6,500 shares of Replimune Group stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total transaction of $52,065.00. Following the sale, the insider owned 151,588 shares of the company’s stock, valued at approximately $1,214,219.88. The trade was a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

A number of hedge funds have recently made changes to their positions in REPL. Readystate Asset Management LP raised its holdings in shares of Replimune Group by 1,296.2% during the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after buying an additional 2,433,292 shares during the last quarter. Braidwell LP raised its holdings in Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after purchasing an additional 2,327,205 shares in the last quarter. Balyasny Asset Management L.P. raised its holdings in Replimune Group by 507.4% during the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after purchasing an additional 2,195,448 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Replimune Group during the fourth quarter worth approximately $17,568,000. Finally, Erste Asset Management GmbH raised its holdings in Replimune Group by 13,597.5% during the third quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock worth $7,074,000 after purchasing an additional 1,618,100 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.